Search hospitals > Michigan > Grosse Pointe
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Claim this profileGrosse Pointe, Michigan 48236
Global Leader in Parotid Gland Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cervical Adenocarcinoma
153 reported clinical trials
6 medical researchers
Summary
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center is a medical facility located in Grosse Pointe, Michigan. This center is recognized for care of Parotid Gland Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cervical Adenocarcinoma and other specialties. Great Lakes Cancer Management Specialists-Van Elslander Cancer Center is involved with conducting 153 clinical trials across 330 conditions. There are 6 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Tareq Al BaghdadiGenesys Hurley Cancer Institute8 years of reported clinical research
Expert in Parotid Gland Cancer
Expert in Cancer
73 reported clinical trials
130 drugs studied
Christopher M. Reynolds, MDSaint Joseph Mercy Hospital2 years of reported clinical research
Expert in Parotid Gland Cancer
Expert in Lung Cancer
51 reported clinical trials
104 drugs studied
Philip J. StellaSaint Joseph Mercy Hospital5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
38 reported clinical trials
89 drugs studied
Elie G. DibGenesys Hurley Cancer Institute6 years of reported clinical research
Expert in Parotid Gland Cancer
Studies Multiple Myeloma
38 reported clinical trials
105 drugs studied
Clinical Trials running at Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Breast Cancer
Lung Cancer
Bladder Cancer
Breast cancer
Parotid Gland Cancer
Multiple Myeloma
Non-Small Cell Lung Cancer
Bladder Carcinoma
Cancer
Cutaneous Melanoma
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Great Lakes Cancer Management Specialists-Van Elslander Cancer Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.